Elesclomol
Elesclomol is a small-molecule investigational drug that has been studied for its potential use in the treatment of cancer. It is known for its ability to induce oxidative stress in cancer cells, leading to apoptosis (programmed cell death).
Mechanism of Action[edit]
Elesclomol works by binding to copper ions and generating reactive oxygen species (ROS) within cancer cells. This increase in ROS levels leads to oxidative stress, which can trigger apoptosis in cancer cells. The drug specifically targets cells with high metabolic activity, which is a characteristic of many cancer cells.
Clinical Development[edit]
Elesclomol has undergone various phases of clinical trials to evaluate its efficacy and safety in treating different types of cancer. It has been studied both as a monotherapy and in combination with other chemotherapeutic agents.
Phase I Trials[edit]
In Phase I clinical trials, the primary objective was to determine the safety, tolerability, and optimal dosing of elesclomol. These trials involved patients with advanced solid tumors and provided preliminary evidence of the drug's activity.
Phase II Trials[edit]
Phase II trials focused on assessing the efficacy of elesclomol in specific types of cancer, such as melanoma. These studies aimed to determine the drug's impact on tumor growth and patient survival rates.
Phase III Trials[edit]
Phase III trials are large-scale studies designed to confirm the efficacy and safety of elesclomol in a broader patient population. These trials compare the outcomes of patients receiving elesclomol with those receiving standard treatments.
Potential Side Effects[edit]
As with many cancer therapies, elesclomol can cause side effects. Common side effects observed in clinical trials include fatigue, nausea, and anemia. More severe side effects may occur, and patients undergoing treatment with elesclomol are closely monitored.
Research and Future Directions[edit]
Research on elesclomol continues, with ongoing studies exploring its potential use in combination with other therapies and in different types of cancer. The drug's ability to induce oxidative stress in cancer cells makes it a promising candidate for further investigation.
See Also[edit]
References[edit]
External Links[edit]
-
 | This medical article is a stub. You can help WikiMD by expanding the page. |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
